Safety and immunogenicity of SIIPL Tdap, a new tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, in healthy subjects 4-65  years of age: A Phase II/III randomized, observer-blinded, active controlled, multicenter clinical study in Germany

CONCLUSIONS: Booster vaccination with SIIPL Tdap was non-inferior to comparator Tdap with respect to the immunogenicity of the vaccine components and was equally well tolerated. EudraCT number: 2019-002706-46.PMID:37827966 | DOI:10.1016/j.vaccine.2023.09.060

Source: Vaccine - October 12, 2023 Category: Allergy & Immunology Authors: Inci Aydin Marcus May Fabio Pisano Nontsikelelo Mpofu-Maetzig Leander Grode Sameer Parekh Pramod Pujari Sunil Shewale Shivani Desai Hitt Sharma Harish Rao Manish Gautam Sunil Gairola Umesh Shaligram Source Type: research